The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
Open accessAbstract
Purpose: The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer. Patients and Methods: Between June 1997 and March 2000, 1,999 patients with operable node-positive breast cancer were randomly assigned to either FEC every 21 days for six cycles, or three cycles of FEC followed by three cycles of docetaxel, both given every 21 days. Hormone-receptor–positive patients received tamoxifen for 5 years after chemotherapy. The primary end point was 5-year disease-free survival (DFS). Results: Median follow-up was 60 months. Five-year DFS rates were 73.2% with FEC and 78.4% with FEC-D (unadjusted P = .011; adjusted P = .012). Multivariate analysis adjusted for prognostic factors showed an 18% reduction in the relative risk of relapse with FEC-D. Five-year overall survival rates were 86.7% with FEC and 90.7% with FEC-D, demonstrating a 27% reduction in the relative risk of death (unadjusted P = .014; adjusted P = .017). The incidence of grade 3 to 4 neutropenia, the need for hematopoietic growth factor, and incidence of nausea/vomiting were higher with FEC. Docetaxel was associated with more febrile neutropenia in the fourth cycle, stomatitis, edema, and nail disorders. Though rare overall, there were fewer cardiac events after FEC-D (P = .03), attributable mainly to the lower anthracycline cumulative dose. Conclusion: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Adjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., Wickerham, D. L., Yothers, G., Soran, A., & Wolmark, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.517 · Cited by 714
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Valero, V, Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 386
Nabholtz, J.-M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., Pienkowski, T., Zaluski, J., Pinter, T., Krzakowski, M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.040 · Cited by 384
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Metadata
- Authors
- Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., Viens, P., Monnier, A., Vindevoghel, A., Campone, M., Goudier, M.-J., Bonneterre, J., Ferrero, J.-M., Martin, A.-L., Genève, J., & Asselain, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-12-20
- Volume
- 24
- Issue
- 36
- Pages
- 5664-5671
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127232551
- Cited by
- 577
- References
- 20
- FWCI
- 15.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. https://app.cochat.ai/papers/10.1200/jco.2006.07.3916
- The paper
- Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., Viens, P., Monnier, A., Vindevoghel, A., Campone, M., Goudier, M.-J., Bonneterre, J., Ferrero, J.-M., Martin, A.-L., Genève, J., & Asselain, B. (2006). Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.07.3916
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.